ACCESS CHINA has been held every quarter since 2020 and serves as a China cross-border corporate access platform. In its 2 years of bringing together international and China Biotech BDs and CEOs, ACCESS CHINA creates invaluable BD opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations. Our 11th “ACCESS CHINA Biotech Forum” has successfully held online on October 12th – 18th, 2022.
During the autumn event, we hosted 70+ selected innovative biotech and pharma looking for out-licensing opportunities in China or globally. There were 500+ pharma BD persons attending the event and seeking licensing opportunities.
The event took place in virtual format on Zoom webinar for company presentations. Each company were given 15mins to present their partnering opportunities.
We welcome the following global pharma and biotech to showcase:
- Looking for out-/in-licensing opportunities in China
- With clinical-stage innovative drug assets
Who are the attendees?
- 50% are Chinese pharma/biotechs looking for in-licensing opportunities to enrich pipeline
- 25% are Pharma/biotech outside China looking for in-licensing opportunities to enrich pipeline in China and other regions
- 15% are VCs and PEs looking for pharma/biotech investment opportunities